Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Effect of EECP on Subclinical Atherosclerosis.

Trial Profile

Study of the Effect of EECP on Subclinical Atherosclerosis.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HMG-CoA reductase inhibitors (Primary)
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms SESA

Most Recent Events

  • 02 Nov 2020 Biomarkers information updated
  • 26 Dec 2012 Planned end date changed from 1 Apr 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
  • 21 May 2012 Trial phase changed from II to I as reported by Chinese Clinical Trial Register record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top